Business Information
The group's principal activities are developing, manufacturing and distributing pharmaceutical products. The group develops generic formulations of medications for the treatment of chronic medical conditions. The services of the group include pharmaceutical development, from research and development, through clinical testing and regulatory filings to full-scale manufacturing. On 11-Dec-2002, the group acquired pharma pass llc & pharma pass sa. Product sales accounted for 58% of 2001 revenues; research and development, 28% and royalty and licensing, 14%.
|
|
Name |
Title
|
Email
|
| Douglas Squires | Chmn., CEO | N/A | | Kenneth Howling | Sr. VP, CFO | N/A | | Chris Bovaird | VP - Corporate Taxation | N/A | | Gilbert Godin | Sr. VP - Technical Operations, Drug Delivery | N/A | | Gregory Gubitz | Sr. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,070,529 | 203,948 | | 2005 | 935,536 | 236,221 | | 2004 | 886,543 | 160,994
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
